MedTrace Logo

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

NCT01818856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-04-22

No results posted yet for this study

Summary

Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues (NRTIs) in HCV/HIV-co-infected patients.

Conditions

  • Hepatitis C, Chronic
  • HIV Infection

Interventions

DRUG

Ritonavir withdrawal, atazanavir 200 mg/12h

DRUG

Telaprevir interactions

Sponsors & Collaborators

Principal Investigators

  • Luis F Lopez-Cortes, MD, PhD. · Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla. Spain.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01818856 on ClinicalTrials.gov